Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Allergan plc (NYSE: AGN).

Full DD Report for AGN

You must become a subscriber to view this report.


Recent News from (NYSE: AGN)

Botox Knock Off Could Change Fortunes For Evolus
Source: pulsenews.co.kr All eyes were on Evolus ( EOLS ) Wednesday as the market awaited a U.S. Food and Drug Administration decision pursuant to PrabotulinumtoxinA (DWP-450), the company's injectable 900 kDa botulinum toxin type A complex designed to address the needs of the facial aesth...
Source: SeekingAlpha
Date: May, 17 2018 14:36
Novartis In Liver Diseases NASH And PBC: A Look At The Bright Side
There can be no greater gift than that of giving one’s time and energy to help others without expecting anything in return. —Nelson Mandela Novartis AG (NVS) is a Swiss (Basel, Switzerland) multibillion biopharmaceutical company with a market cap of $178B and a broad the...
Source: SeekingAlpha
Date: May, 17 2018 14:35
Teva's Generic Restasis Could Punish Allergan
Source: newswire.ca Last week Teva ( TEVA ) announced it had launched a generic version of Allergan's ( AGN ) blockbuster dry-eye drug Restasis in Canada: Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries Ltd., announced the launch of Teva-Cyclosporine® op...
Source: SeekingAlpha
Date: May, 17 2018 01:56
Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?
Investment Thesis Despite the missteps by Synergy ( SGYP ) management that have taken a toll on the share price for more than a year, it remains there is little doubt that Trulance is a highly differentiated product with a patent extending until March 2032 and it remains only one of three...
Source: SeekingAlpha
Date: May, 16 2018 16:58
FDA OKs first non-opioid treatment for opioid withdrawal
The FDA approves privately held US WorldMeds LLC's Lucemyra (lofexidine hydrochloride) for the management of opioid withdrawal symptoms in adults who abruptly discontinue opioids. More news on: Endo International plc, Allergan plc, Johnson & Johnson, Healthcare stocks news, Read ...
Source: SeekingAlpha
Date: May, 16 2018 16:44
Allergan to Present at the Bernstein Strategic Decisions Conference
DUBLIN , May 16, 2018 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global biopharmaceutical company, today announced that Chairman and CEO Brent Saunders will present at the Bernstein 34 th Annual Strategic Decisions Conference in New York, NY . The presentation will begin...
Source: PR Newswire
Date: May, 16 2018 16:15
Mexico Sees Slim Chances For A New NAFTA Deal; The IEA Expects The Oil Price Spike To Take A Toll (Wall Street Breakfast Podcast)
Get today's Wall Street Breakfast in podcast form to listen on the go. Today's top stories: In today's top stories: Mexico sees slim chances for a new NAFTA deal; the IEA expects the oil price spike to take a toll; and Amazon fires a new salvo in the supermarket wars. If you are...
Source: SeekingAlpha
Date: May, 16 2018 08:53
Wall Street Breakfast: Clock Ticks Down For New NAFTA
Mexico sees diminishing chances for a new NAFTA deal ahead of tomorrow's deadline - given by U.S. House Speaker Paul Ryan - that would allow for the pact to be approved before a newly elected Congress takes over in January. Further complicating talks are Mexico's presidential elect...
Source: SeekingAlpha
Date: May, 16 2018 07:02
Glenview added Express Scripts, exited Apple in Q1
Larry Robbins and Mark Horowitz's Glenview Capital discloses the addition of Express Scripts (NASDAQ: ESRX ) to its investments while exiting Apple (NASDAQ: AAPL ) in Q1, according to its 13F filing . More news on: Express Scripts, Inc., Apple Inc., T-Mobile US, Inc., Read more ...
Source: SeekingAlpha
Date: May, 15 2018 17:11
Kiniksa Pharmaceuticals Aims For $126 Million U.S. IPO
Quick Take Kiniksa Pharmaceuticals ( KNSA ) intends to raise $126 million in a U.S. IPO of its Class A common stock, according to an amended S-1/A registration statement . The company is developing a pipeline of drug treatments for autoinflammatory and autoimmune diseases. KNSA is mak...
Source: SeekingAlpha
Date: May, 15 2018 12:38

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-18154.59160.23160.36154.2933,492,604
2018-05-17154.59160.23160.36154.2933,492,504
2017-11-08173.00175.01175.35173.002,917,074
2017-11-07175.00172.97175.34172.694,257,803
2017-11-06175.00174.34177.61173.984,057,996

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1316,60841,81339.7197Short
2018-08-1027,06944,14061.3253Short
2018-08-0913,26969,53919.0814Cover
2018-08-084,74429,27916.2027Cover
2018-08-0722,24378,41728.3650Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AGN.


About Allergan plc (NYSE: AGN)

Logo for Allergan plc (NYSE: AGN)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $52,103,907,561 - 05/11/2018
  • Issue and Outstanding: 339,063,627 - 04/27/2018

 


Recent Filings from (NYSE: AGN)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 03 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 03 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 16 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 09 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 06 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 23 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 23 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: March, 13 2018
Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Filing Type: 25-NSEFiling Source: edgar
Filing Date: March, 01 2018

 

 


Daily Technical Chart for (NYSE: AGN)

Daily Technical Chart for (NYSE: AGN)


Stay tuned for daily updates and more on (NYSE: AGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NYSE: AGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AGN and does not buy, sell, or trade any shares of AGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/